Main > ONCOLOGY (**) > Esophageal>Squamous>Advanced>R> > TREAT.: > USA. M. PembrolizuMAb
USA. M. PembrolizuMAb's subsections
(*) CN Approval Date: 2020. 06.22.
(*) JP Approval Date: 2020. 08.24
(*) USA Approval Date: 2019. 07.31.
2nd Line Treat.>1 Prior Lines Syste
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 6
Patent>UpDate: 2019. 12.31.
TradeMark
TradeMark Web-Site
whose tumors express PD-L1 (CPS
USA. M. PembrolizuMAb's products
This section has no products